Genetics-Supported Mainstream Testing Improves Access and Efficiency for Patients With Breast Cancer
Journal of the National Comprehensive Cancer Network · 2026-08 · 24 (8)
DOI: 10.6004/jnccn.2026.7020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-08. Verfasst von Kristen M Shannon und 7 weiteren Autor:innen. Beteiligte Einrichtung: 1Center for Cancer Risk Assessment, Massachusetts General Hospital Cancer Center, Boston, MA. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Testing, Health Services Accessibility. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
The demand for germline genetic testing in oncology is outpacing traditional genetics service capacity. Mainstream genetic testing, where oncologists initiate testing with structured support, may expand access while maintaining quality. Patients and Methods: We performed a retrospective chart review of patients with breast cancer who underwent germline genetic testing at Massachusetts General Hospital from March 2021 to July 2022. Patients were managed via either a traditional model (genetics professional–led) or a genetics supported mainstream model (oncologist-led, with genetic counseling assistant support). Outcomes included test volume, turnaround times, documentation of consent and results disclosure, and follow-up for pathogenic variant (PV) carriers.
Results
Among 805 patients (traditional: n=305; mainstream: n=500), the mainstream model significantly shortened the interval from diagnosis to consent (22.4 vs 59.5 days; P 99% in both models. However, documentation of final result disclosure was significantly lower in the mainstream model (82.4% vs 100%; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- 1Center for Cancer Risk Assessment, Massachusetts General Hospital Cancer Center, Boston, MA.
- 2Department of Medicine, Massachusetts General Hospital, Boston, MA.
- 3Genetic Counseling Department, MGH Institute for Health Professions, Charlestown, MA.
- 4Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Zitieren
APA
Shannon, K. M., Wooters, M., Fell, G. G., Kelly, H., Patel, D., Urban, T. X., Nieters, A. M., & Micalizzi, D. S. (2026). Genetics-Supported Mainstream Testing Improves Access and Efficiency for Patients With Breast Cancer. Journal of the National Comprehensive Cancer Network, 24(8). https://doi.org/10.6004/jnccn.2026.7020
Vancouver
Shannon KM, Wooters M, Fell GG, Kelly H, Patel D, Urban TX, et al. Genetics-Supported Mainstream Testing Improves Access and Efficiency for Patients With Breast Cancer. Journal of the National Comprehensive Cancer Network. 2026;24(8). doi:10.6004/jnccn.2026.7020
BibTeX
@article{Shannon2026,
author = {Shannon, Kristen M and Wooters, Mackenzie and Fell, Geoffrey G and Kelly, Hannah and Patel, Devanshi and Urban, Taylor X and Nieters, Amanda M and Micalizzi, Douglas S},
title = {Genetics-Supported Mainstream Testing Improves Access and Efficiency for Patients With Breast Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {8},
doi = {10.6004/jnccn.2026.7020}
}
EUVIMED